Treatment with teprotumumab is associated with a reduction in intraocular pressure (IOP) in patients with thyroid eye disease (TED), according to a study.
In this retrospective review, the IOP, extent of proptosis, and clinical activity score of 17 patients (34 eyes) with TED who were treated with teprotumumab were analyzed at baseline and at 6 weeks, 12 weeks, and 24 weeks after starting treatment.
The mean baseline IOP and clinical activity score was 20 mm Hg (range 13-28) and 3.8 (range 0-6), respectively.
At week 6 of treatment, of the 16 eyes examined, there was a mean IOP decrease of 4.9 mm Hg (P < 0.0001). At week 12 of treatment, of the 26 eyes examined, there was a mean IOP decrease of 4.6 mm Hg (P < 0.0001). At week 24 of treatment, of the 8 eyes examined, there was a mean IOP decrease of 4.9 mm Hg (P < 0.0001).
Reference
Adetunji MO, Nguyen BJ, McGeehan B, et al. Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy. Taiwan J Ophthalmol. 2022;12(3):325-329. doi: 10.4103/tjo.tjo_30_22. PMID: 36248076; PMCID: PMC9558482.
Related Content
